Most studies have assayed KRAS oncogene mutations to identify circulating tumor DNA (ctDNA), and several groups, including ours, have reported that the presence of a KRAS mutation has a negative influence on the prognosis of pancreatic cancer patients [7,8,9,10]. Here, KRAS is linked to familial pancreatic carcinoma.